Natera, Inc.
NTRA · Nasdaq
NTRA · Nasdaq
Natera is a genetic-testing company that sells diagnostic services, including Signatera, which is used in cancer testing and is seeking approval in Japan as a companion diagnostic for muscle-invasive bladder cancer. The supplied evidence does not provide a segment breakdown or quantify how much revenue comes from oncology versus other testing activities, nor does it specify customer shares by patients, physicians, hospitals, or other providers. Natera reports $2.3 billion of FY2025 revenue, up from $1.7 billion in FY2024, while net income remains negative at approximately $0.2 billion in each year.
Natera rose $22.97, or 9.11%, from $252.22 to $275.19 across the supplied week. Trading was initially subdued, with a 0.6% gain on July 29, before the stock jumped 6.2% on July 30; it then gave back 0.7% on July 31, recovered 1.0% on Aug. 3 and added 1.8% on Aug. 4. The clearest company-specific item was Natera’s filing for Japan PMDA approval to use Signatera as a companion diagnostic in muscle-invasive bladder cancer, but the evidence does not establish that it caused the July 30 surge. A separate report flags NTRA among ETFs with week-over-week share changes, without quantifying NTRA’s inflow. Thus, the week’s move is only partly explained by disclosed news.
